Market Overview

New Research: Key Drivers of Growth for Guess?, Acer Therapeutics, American National Insurance, J P Morgan Chase, Juno Therapeutics, and Allergan — Factors of Influence, Major Initiatives and Sustained Production

Share:

NEW YORK, Feb. 01, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Guess?, Inc. (NYSE:GES), Acer Therapeutics, Inc. (NASDAQ:ACER), American National Insurance Company (NASDAQ:ANAT), J P Morgan Chase & Co (NYSE:JPM), Juno Therapeutics, Inc. (NASDAQ:JUNO), and Allergan PLC. (NYSE:AGN), including updated fundamental summaries, consolidated fiscal reporting, and fully-qualified certified analyst research.

Complimentary Access: Research Reports

Full copies of recently published reports are available to readers at the links below.

GES DOWNLOAD: http://Fundamental-Markets.com/register/?so=GES
ACER DOWNLOAD:
http://Fundamental-Markets.com/register/?so=ACER
ANAT DOWNLOAD:
http://Fundamental-Markets.com/register/?so=ANAT
JPM DOWNLOAD:
http://Fundamental-Markets.com/register/?so=JPM
JUNO DOWNLOAD:
http://Fundamental-Markets.com/register/?so=JUNO
AGN DOWNLOAD:
http://Fundamental-Markets.com/register/?so=AGN

(You may have to copy and paste the link into your browser and hit the [ENTER] key)

The new research reports from Fundamental Markets, available for free download at the links above, examine Guess?, Inc. (NYSE:GES), Acer Therapeutics, Inc. (NASDAQ:ACER), American National Insurance Company (NASDAQ:ANAT), J P Morgan Chase & Co (NYSE:JPM), Juno Therapeutics, Inc. (NASDAQ:JUNO), and Allergan PLC. (NYSE:AGN) on a fundamental level and outlines the overall demand for their products and services in addition to an in-depth review of the business strategy, management discussion, and overall direction going forward. Several excerpts from the recently released reports are available to today's readers below.

-----------------------------------------

Important Notice: the following excerpts are not designed to be standalone summaries and as such, important information may be missing from these samples. Please download the entire research report, free of charge, to ensure you are reading all relevant material information. All information in this release was accessed January 30th, 2018. Percentage calculations are performed after rounding. All amounts in millions (MM), except per share amounts.

-----------------------------------------

GUESS?, INC. (GES) REPORT OVERVIEW

Guess?'s Recent Financial Performance

For the three months ended October 31st, 2017 vs October 31st, 2016, Guess? reported revenue of $554.14MM vs $536.32MM (up 3.32%) and basic earnings per share -$0.04 vs $0.11. For the three months ended October 31st, 2017 vs October 31st, 2016, Guess? reported interest income of $*** For the twelve months ended January 31st, 2017 vs January 31st, 2016, Guess? reported revenue of $2,209.37MM vs $2,204.31MM (up 0.23%) and basic earnings per share $0.27 vs $0.97 (down 72.16%). For the twelve months ended January 31st, 2017 vs January 31st, 2016, Guess? reported interest income of $*** Guess? is expected to report earnings on March 21st, 2018. The report will be for the fiscal period ending January 31st, 2018. The reported EPS for the same quarter last year was $0.41. The estimated EPS forecast for the next fiscal year is $0.84 and is expected to report on March 21st, 2018.

To read the full Guess?, Inc. (GES) report, download it here: http://Fundamental-Markets.com/register/?so=GES

-----------------------------------------

ACER THERAPEUTICS, INC. (ACER) REPORT OVERVIEW

Acer Therapeutics' Recent Financial Performance

For the twelve months ended December 31st, 2016 vs December 31st, 2015, Acer Therapeutics reported revenue of $2.91MM vs $2.56MM (up 13.65%) and basic earnings per share -$11.70 vs -$21.22. Acer Therapeutics is expected to report earnings on March 27th, 2018. The report will be for the fiscal period ending December 31st, 2017. The estimated EPS forecast for the next fiscal year is -$2.76 and is expected to report on March 27th, 2018.

To read the full Acer Therapeutics, Inc. (ACER) report, download it here: http://Fundamental-Markets.com/register/?so=ACER

-----------------------------------------

AMERICAN NATIONAL INSURANCE COMPANY (ANAT) REPORT OVERVIEW

American National Insurance's Recent Financial Performance

For the three months ended September 30th, 2017 vs September 30th, 2016, American National Insurance reported revenue of $872.75MM vs $823.14MM (up 6.03%) and basic earnings per share $2.72 vs $2.20 (up 23.64%). For the twelve months ended December 31st, 2016 vs December 31st, 2015, American National Insurance reported revenue of $3,227.95MM vs $3,017.46MM (up 6.98%) and basic earnings per share $6.73 vs $9.04 (down 25.55%). American National Insurance is expected to report earnings on February 26th, 2018. The report will be for the fiscal period ending December 31st, 2017.

To read the full American National Insurance Company (ANAT) report, download it here: http://Fundamental-Markets.com/register/?so=ANAT

-----------------------------------------

J P MORGAN CHASE & CO (JPM) REPORT OVERVIEW

J P Morgan Chase's Recent Financial Performance

J P Morgan Chase is expected to report earnings on April 12th, 2018. The report will be for the fiscal period ending March 31st, 2018. According to Zacks Investment Research, based on 8 analysts' forecasts, the consensus EPS forecast for the quarter is $1.69. The reported EPS for the same quarter last year was $1.65. The estimated EPS forecast for the next fiscal year is $9.57 and is expected to report on January 11th, 2019.

To read the full J P Morgan Chase & Co (JPM) report, download it here: http://Fundamental-Markets.com/register/?so=JPM

-----------------------------------------

JUNO THERAPEUTICS, INC. (JUNO) REPORT OVERVIEW

Juno Therapeutics' Recent Financial Performance

For the three months ended September 30th, 2017 vs September 30th, 2016, Juno Therapeutics reported revenue of $44.82MM vs $20.83MM (up 115.19%) and basic earnings per share -$1.12 vs -$0.56. For the twelve months ended December 31st, 2016 vs December 31st, 2015, Juno Therapeutics reported revenue of $79.36MM vs $18.22MM (up 335.66%) and basic earnings per share -$2.42 vs -$2.72. Juno Therapeutics is expected to report earnings on March 7th, 2018. The report will be for the fiscal period ending December 31st, 2017. The reported EPS for the same quarter last year was -$0.66. The estimated EPS forecast for the next fiscal year is -$4.40 and is expected to report on March 7th, 2018.

To read the full Juno Therapeutics, Inc. (JUNO) report, download it here: http://Fundamental-Markets.com/register/?so=JUNO

-----------------------------------------

ALLERGAN PLC. (AGN) REPORT OVERVIEW

Allergan's Recent Financial Performance

For the three months ended September 30th, 2017 vs September 30th, 2016, Allergan reported revenue of $4,034.30MM vs $3,622.20MM (up 11.38%) and basic earnings per share -$12.07 vs $38.58. For the twelve months ended December 31st, 2016 vs December 31st, 2015, Allergan reported revenue of $14,570.60MM vs $12,688.10MM (up 14.84%) and basic earnings per share $38.18 vs $10.01 (up 281.42%). Allergan is expected to report earnings on February 6th, 2018. The report will be for the fiscal period ending December 31st, 2017. The reported EPS for the same quarter last year was $3.90. The estimated EPS forecast for the next fiscal year is $15.45 and is expected to report on February 6th, 2018.

To read the full Allergan PLC. (AGN) report, download it here: http://Fundamental-Markets.com/register/?so=AGN

-----------------------------------------

ABOUT FUNDAMENTAL MARKETS

Fundamental Markets serves thousands of members and have provided research through some of the world's leading brokerages for over a decade–and continue to be one of the best information sources for investors and investment professionals worldwide. Fundamental Markets' roster boasts decades of financial experience and includes top financial writers, FINRA® BrokerCheck® certified professionals with current and valid CRD® number designations, as well as Chartered Financial Analyst® (CFA®) designation holders, to ensure up to date factual information for active readers on the topics they care about.

REGISTERED MEMBER STATUS

Fundamental Markets' oversight and audit staff are registered analysts, brokers, and/or financial advisers ("Registered Members") working within Equity Research, Media, and Compliance departments. Fundamental Markets' roster includes qualified CFA® charterholders, licensed securities attorneys, and registered FINRA® members holding duly issued CRD® numbers. Current licensed status of several Registered Members at Fundamental Markets have been independently verified by an outside audit firm, including policy and audit records duly executed by Registered Members. Complaints, concerns, questions, or inquiries regarding this release should be directed to Fundamental Markets' Compliance department by Phone, at +1 667-401-0010, or by E-mail at compliance@Fundamental-Markets.com.

LEGAL NOTICES

Information contained herein is not an offer or solicitation to buy, hold, or sell any security. Fundamental Markets, Fundamental Markets members, and/or Fundamental Markets affiliates are not responsible for any gains or losses that result from the opinions expressed. Fundamental Markets makes no representations as to the completeness, accuracy, or timeliness of the material provided and all materials are subject to change without notice. Fundamental Markets has not been compensated for the publication of this press release by any of the above mentioned companies. Fundamental Markets is not a financial advisory firm, investment adviser, or broker-dealer, and does not undertake any activities that would require such registration. For our full disclaimer, disclosure, and terms of service please visit our website.

Media Contact:
Andrew Duffie, Media Department
Office: +1 667-401-0010
E-mail: media@Fundamental-Markets.com

© 2018 Fundamental Markets. All Rights Reserved. For republishing permissions, please contact a partner network manager at partnership@Fundamental-Markets.com.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

FINRA®, BrokerCheck®, and CRD® are registered trademarks owned by Financial Industry Regulatory Authority, Inc.

View Comments and Join the Discussion!